Biological and clinical aspects to better understand osteosarcoma
Keywords:
Osteosarcoma,, molecular mechanisms of osteosarcoma, treatments for osteosarcoma, malignant neoplasmAbstract
The ostosarcoma is a malignant neoplasm from bone origin commonly presented during the
second life decade. In Mexico, the available information about this pathology is focuses mainly
in clinic area, however is fundamental to know the molecular aspects involved in this patho-
logical process. This review shows a general view concerning the clinical and epidemiological
information about osteosarcoma and discusses in a more detail the knowledge generated about
the molecular mechanisms involved in the development of this pathology.
Publication Facts
Reviewer profiles N/A
Author statements
Indexed in
- Editor & editorial board
- profiles
- Academic society
- N/A
To learn about these publication facts, click 
PF is maintained by the Public Knowledge Project
References
Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet
J Rare Dis. 2007; 23: 2-6.
J-Klein M, P-Siegal G. Osteosarcoma anatomic and
histologic variants. Am J Clin Pathol 2006; 125: 555-581.
Broadhead ML, Clark JC, Myers DE, Dass CR, Choong
PF. The molecular pathogenesis of osteosarcoma: A
review. Sarcoma. 2011; 2011. Article ID 959248, pages
doi: 10.1155/2011/959248.
Zhu L, McManus MM, Hughes DP. Understanding the
biology of bone sarcoma from early initiating events
through late events in metastasis and disease progres-
sion. Front Oncol. 2013; 17: 1-17.
Cuevas-Urióstegui ML, Villasis-Keever MA, Fajardo-
Gutiérrez A. Epidemiología del cáncer en adolescentes.
Salud Pública de México. 2003; 45: 115-123.
Baena-Ocampo LC, Ramírez-Pérez E, Linares-
González LM, Delgado-Chávez R. Epidemiology of bone
tumors in Mexico City: retrospective clinicopathologic
study of 566 patients at a referral institution. Ann Diagn
Pathol. 2009; 13: 16-21.
Nthumba PM. Osteosarcoma of the jaws: a review of
literature and a case report on synchronous multicentric
osteosarcomas. World J Surg Oncol. 2012; 10: 240.
Thariat J et al. Osteosarcomas of the mandible: Are
they different from other tumor sites? Crit Rev Oncol
Hematol. 2012; 82 (3): 280-95.
Neyssa M, Gebhardt M. Biology and therapeutic ad-
vances for pediatric osteosarcoma. The Oncologist.
; 9: 422-441.
Mirabello L, Troisi R, Savage SA. Osteosarcoma inci-
dence and survival rates from 1973 to 2004: Data from
the surveillance, epidemiology, and end results program.
Cancer. 2009; 7: 1531-1543.
Savage A, Mirabello A. Epidemiology and genomics
to understand osteosarcoma etiology. Sarcoma. 2011;
: 1-13.
Las-Heras F, Fernández GF, Capdeville FF. Osteosar-
comas de la región de cabeza y cuello. Rev Chilena de
Cirugía. 20011; 63 (5): 468-472.
McIntyre JF et al. Germline mutations of the p53 tumor
suppressor gene in children with osteosarcoma. J Clin
Oncol. 1994; 12 (5): 925-930.
Franchi A, Arganini L, Baroni G et al. Expression of
transforming growth factor beta isoforms in osteosar-
coma variants: association of TGF beta 1 with high grade
osteosarcomas. J Pathol. 1998; 185: 284-289.
Burrow S, Andrulis IL, Pollak M, Bell RS. Expression of
insulin-like growth factor receptor, IGF-1, and IGF-2 in
primary and metastatic osteosarcoma. J Surg Oncol.
; 69: 21-27.
Nishida T, Nakanishi T, Asano M, Shimo T, Takigawa
M. Effects of CTGF/Hcs24, a hypertrophic chondrocyte-
specifi c gene product, on the proliferation and differen-
tiation of osteoblastic cells in vitro. J Cell Physiol. 2000;
: 197-206.
Nishida T, Emura K, Kubota S, Lyons KM, Takigawa M.
CCN family 2/connective tissue growth factor (CCN2/
CTGF) promotes osteoclastogenesis via induction of
and interaction with dendritic cell-specifi c transmem-
brane protein (DC-STAMP). J Bone Miner Res. 2011;
: 351-63.
Man T-K, Lu X-T, Jaeweon K. Genome-wide array
comparative genomic hybridization analysis reveals
distinct amplifi cations in osteosarcoma. BMC Cancer.
; 4: 45.
Suehara Y, Kubota D, Kikuta K. Discovery of Biomarkers
for osteosarcoma by proteomics approaches. Sarcoma.
; 11-15.
Li FP et al. A cancer family syndrome in twenty-four
kindreds. Cancer Res. 1988; 48: 5358-5362.
Malkin D et al. Germ line p53 mutations in a familial
syndrome of breast cancer, sarcomas, and other neo-
plasms. Science. 1990; 30: 1233-1238.
Franco-Hernández C, Martínez-Glez V, Rey JA. Biología
molecular de los glioblastomas. Neurocirugía. 2007; 18:
-382.
Pasello M et al. Overcoming glutathione S-transferase
P1-related cisplatin resistance in osteosarcoma. Cancer
Res. 2008; 68 (16): 6661-8.
Na KY, Kim YW, Park YK. Mitogen-activated protein
kinase pathway in osteosarcoma. Pathology. 2012; 44
(6): 540-6.
Jenette K et al. Therapeutics, targets, and chemical
biology expression and function of survivin in canine
osteosarcoma. Cancer Res. 2012; 72: 249-259.
Wan et al. Oncogenic roles of astrocyte elevated gene-1
(AEG-1) in osteosarcoma progression and prognosis.
Cancer Biol Ther. 2011; 12 (6): 539-548.
Lu XY et al. Cell cycle regulator gene CDC5L, a poten-
tial target for 6p12-p21 amplicon in osteosarcoma. Mol
Cancer Res. 2008; 6: 937-46.
Zhang Z et al. Comparative proteomic analysis of plasma
membrane proteins between human osteosarcoma and
normal osteoblastic cell lines. BioMed Central Cancer.
; 10: 206.
Buecker P, Gebhardt M, Weber K. Osteosarcoma
[Internet]. Liddy Shriver Sarcoma Initiative [Fecha de
consulta: 30 octubre de 2013]. Disponible en: http://
sarcomahelp.org/translate/es-osteosarcoma.html
Muscolo D et al. Actualización en osteosarcoma. Rev
Asoc Argent Ortop Traumatol. 2009: 74 (1): 86-101.
Alderden R et al. The discovery and development of
cisplatin. J Chem. 2006; 83: 728-724.
Hospital Infantil de México Federico Gómez [Página
Web]. Protocolo de tratamiento de osteosarcoma en el
Hospital Infantil de México Federico Gómez [Fecha de
consulta: 30 de octubre de 2013]. Disponible en: http://
www.himfg.edu.mx/descargas/documentos/planeacion/
guiasclinicasHIM/Osteosarcoma.pdf
Yancey A et al. Risk factors for cisplatin-associated
ototoxicity in pediatric oncology patients. Pediatr Blood
Cancer. 2012; 59: 144-148.
Pérez C et al. Cardiotoxicidad tardía inducida por an-
traciclinas. Med Clin (Barc). 2009; 133 (8): 311-313.
Sociedad Española de Farmacéuticos de Hospitales.
Medicamentos citostáticos. 4a ed. Madrid: Raíz; 2005.
Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Ta-
miniau AH, Hogendoorn PC et al. Chemotherapeutic
adjuvant treatment for osteosarcoma: where do we
stand? Eur J Cancer. 2011; 47 (16): 2431-45.
Akiyama T, R-Dass C, M-Choong P. Novel therapeutic
strategy for osteosarcoma targeting osteoclast differen-
tiation, bone resorbing activity, and apoptosis pathway.
Mol Cancer Ther. 2008; 7: 3461-3469.
Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosar-
coma treatment: state of the art. Cancer Metastasis Rev.
; 28: 247-263.
Akiyama T, R-Dass C, M-Choong P. Novel therapeutic
strategy for osteosarcoma targeting osteoclast differen-
tiation, bone resorbing activity, and apoptosis pathway.
Mol Cancer Ther. 2008; 7: 3461-3469.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra
This work is licensed under a Creative Commons Attribution 4.0 International License.
© Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which allows to reproduce and modify the content if appropiate recognition to the original source is given.
